Nymox Pharmaceutical Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.3400
- Today's High:
- $0.3600
- Open Price:
- $0.3600
- 52W Low:
- $0.19
- 52W High:
- $2.1
- Prev. Close:
- $0.3546
- Volume:
- 73347
Company Statistics
- Market Cap.:
- $0.032 billion
- Book Value:
- 0.024
- Revenue TTM:
- $0.000 billion
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0.000 billion
- Gross Profit TTM:
- $0.000 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- -145.2%
- Return on Equity TTM:
- -284%
Company Profile
Nymox Pharmaceutical Corp had its IPO on 1997-12-22 under the ticker symbol NYMX.
The company operates in the LIFE SCIENCES sector and IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry. Nymox Pharmaceutical Corp has a staff strength of 0 employees.
Stock update
Shares of Nymox Pharmaceutical Corp opened at $0.36 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $0.34 - $0.36, and closed at $0.35.
This is a -2.14% slip from the previous day's closing price.
A total volume of 73,347 shares were traded at the close of the day’s session.
In the last one week, shares of Nymox Pharmaceutical Corp have increased by 0%.
Nymox Pharmaceutical Corp's Key Ratios
Nymox Pharmaceutical Corp has a market cap of $0.032 billion, indicating a price to book ratio of 14.56 and a price to sales ratio of 25395.11.
In the last 12-months Nymox Pharmaceutical Corp’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.013 billion. The EBITDA ratio measures Nymox Pharmaceutical Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nymox Pharmaceutical Corp’s operating margin was 0% while its return on assets stood at -145.2% with a return of equity of -284%.
In Q2, Nymox Pharmaceutical Corp’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Nymox Pharmaceutical Corp’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.183 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nymox Pharmaceutical Corp’s profitability.
Nymox Pharmaceutical Corp stock is trading at a EV to sales ratio of 28731.51 and a EV to EBITDA ratio of -2.264. Its price to sales ratio in the trailing 12-months stood at 25395.11.
Nymox Pharmaceutical Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Nymox Pharmaceutical Corp ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Nymox Pharmaceutical Corp ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Nymox Pharmaceutical Corp’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Nymox Pharmaceutical Corp's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Nymox Pharmaceutical Corp paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $0.35
- 52-Week High
- $2.1
- 52-Week Low
- $0.19
- Analyst Target Price
- $10.25
Nymox Pharmaceutical Corp stock is currently trading at $0.35 per share. It touched a 52-week high of $2.1 and a 52-week low of $2.1. Analysts tracking the stock have a 12-month average target price of $10.25.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Nymox Pharmaceutical Corp
Similar Industry Stocks (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)
Most Active
Top Gainers
Top Losers
About
Nymox Pharmaceutical Corporation, a biopharmaceutical company, is dedicated to the research and development of medicines for the aging population in Canada, the United States, Europe and internationally. The company is headquartered in Nassau, The Bahamas.